› 3ia6

X-ray diffraction
2.31Å resolution

X-ray Crystal structure of the nuclear hormone receptor PPAR-gamma in a complex with a PPAR gamma/alpha dual agonist

Released:
DOI: 10.2210/pdb3ia6/pdb
PDB entry 3ia6 coloured by chain, front view.
PDB entry 3ia6 coloured by chain, side view.
PDB entry 3ia6 coloured by chain, top view.
Source organism: Homo sapiens
Primary publication:
Synthesis and evaluation of novel alpha-heteroaryl-phenylpropanoic acid derivatives as PPARalpha/gamma dual agonists.
Casimiro-Garcia A, Bigge CF, Davis JA, Padalino T, Pulaski J, Ohren JF, McConnell P, Kane CD, Royer LJ, Stevens KA, Auerbach B, Collard W, McGregor C, Song K
Bioorg Med Chem 17 7113-25 (2009)
PMID: 19783444

Function and Biology Details

Biochemical function:
Biological process:
Cellular component:
Sequence domains:

Structure analysis Details

Assembly composition:
homo dimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-153379 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Peroxisome proliferator-activated receptor gamma Chains: A, B
Molecule details ›
Chains: A, B
Length: 271 amino acids
Theoretical weight: 31 KDa
Source organism: Homo sapiens
Expression system: Escherichia coli
UniProt:
  • Canonical: P37231 (Residues: 235-505; Coverage: 54%)
Gene names: NR1C3, PPARG
Sequence domains: Ligand-binding domain of nuclear hormone receptor
Structure domains: Retinoid X Receptor

Ligands and Environments

1 bound ligand:
Ligand UNT 2 x UNT
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 17-ID
Spacegroup: C2
Unit cell:
a: 93.041Å b: 62.187Å c: 118.547Å
α: 90° β: 102.66° γ: 90°
R-values:
R R work R free
0.241 0.238 0.297
Expression system: Escherichia coli

Quick links

Citations

1 review citation

Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.
Mahdy Ali et al. (2012)
3 other articles

1 mention without citation

Molecular modelling study of the PPARĪ³ receptor in relation to the mode of action/adverse outcome pathway framework for liver steatosis.
Tsakovska et al. (2014)